Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| May 17, 2026 | CGS Administrators | Automated Detection and Quantification of Brain MRIs | Criteria changed |
| May 17, 2026 | CGS Administrators | Automated Detection and Quantification of Brain MRIs | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis | Criteria changed |
| May 17, 2026 | CGS Administrators | Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH) | Criteria changed |
| May 17, 2026 | CGS Administrators | Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Molecular Testing for Solid Organ Allograft Rejection | Criteria changed |
| May 17, 2026 | CGS Administrators | Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) | Criteria changed |
| May 17, 2026 | CGS Administrators | Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms | Criteria changed |
| May 17, 2026 | CGS Administrators | Intervertebral Disc Repair | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Genetic Testing for Heritable Thoracic Aortic Disease | Criteria changed |
| May 17, 2026 | CGS Administrators | Botulinum Toxin Injections | Criteria changed |
| May 17, 2026 | CGS Administrators | Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA) | Criteria changed |
| May 17, 2026 | CGS Administrators | Minimally Invasive Arthrodesis of the Sacroiliac Joint (SIJ) | Criteria changed |
| May 17, 2026 | CGS Administrators | Cervical Fusion | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy | Criteria changed |
| May 17, 2026 | CGS Administrators | Trigger Point Injections (TPI) | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers | Criteria changed |
| May 17, 2026 | CGS Administrators | Urinary Biomarkers for Chronic Pain Management | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma | Criteria changed |
| May 17, 2026 | CGS Administrators | Amniotic and Placental Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound | Criteria changed |
| May 17, 2026 | CGS Administrators | Positron Emission Tomography (PET) Scan for Inflammation and Infection | Criteria changed |
| May 17, 2026 | CGS Administrators | Cosmetic and Reconstructive Surgery | Criteria changed |
| May 17, 2026 | CGS Administrators | Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma | Criteria changed |
| May 17, 2026 | CGS Administrators | Sacroiliac Joint Injections and Procedures | Criteria changed |
| May 17, 2026 | CGS Administrators | Prostate Cancer Detection with IsoPSA® | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing | Criteria changed |
| May 17, 2026 | CGS Administrators | Platelet Rich Plasma Injections for Non-Wound Injections | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer | Criteria changed |
| May 17, 2026 | CGS Administrators | Epidural Steroid Injections for Pain Management | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer | Criteria changed |
| May 17, 2026 | CGS Administrators | Electroretinography (ERG) | Criteria changed |
| May 17, 2026 | CGS Administrators | Off-label Use of Rituximab and Rituximab Biosimilars | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Minimal Residual Disease Testing for Cancer | Criteria changed |
| May 17, 2026 | CGS Administrators | Colon Capsule Endoscopy (CCE) | Criteria changed |
| May 17, 2026 | CGS Administrators | Facet Joint Interventions for Pain Management | Criteria changed |
| May 17, 2026 | CGS Administrators | Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease | Criteria changed |
| May 17, 2026 | CGS Administrators | Computed Tomography Cerebral Perfusion Analysis (CTP) | Criteria changed |
| May 17, 2026 | CGS Administrators | Implantable Continuous Glucose Monitors (I-CGM) | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Molecular Testing for Solid Organ Allograft Rejection | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Pharmacogenomics Testing | Criteria changed |
| May 17, 2026 | CGS Administrators | Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH) | Criteria changed |